Skip to main content
. 2014 Feb 14;123(13):2108–2115. doi: 10.1182/blood-2013-10-533562

Table 1.

Clinical characteristics of 48 allogeneic HSCT patients

Characteristic −cGVHD* (N = 28) +cGVHD (N = 20) P value
Median age, year (range) 58 (21-73) 51 (28-67) .39
Sex, no. (%) of females 8 (40) 14 (50) .57
Median time after transplant, mo (range) 23 (10-110) 25 (12-116) .96
Conditioning regimen (%)
 Myeloablative 15 (54) 6 (30) .14
 Nonmyeloablative 13 (46) 14 (70)
Source of graft (%)
 Peripheral blood 26 (93) 18 (90) 1.00
 Bone marrow 2 (7) 2 (10)
HLA matching (%)
 Matched, unrelated 8 (29) 10 (50) .15
 Matched, related 18 (64) 7 (35)
 Mismatched 2 (7) 3 (15)
Immunosuppressive treatment (%)
 Prednisone ≤30 mg (2.5-30 mg)/day 4 (14) 12 (60) .002
 MMF 0 (0) 1 (5) .42
 Tacrolimus 5 (18) 6 (30) .49
 Rapamycin 3 (15) 0 (0) .07
 ATG 5 (18) 4 (20) 1.00
 Alemtuzumab 2 (7) 0 (0) .50
aGVHD
 Grade I, no. (%) 7 (25) 8 (40) .74
 Grade II, no. (%) 2 (7) 1 (5)
 Grade III, no. (%) 1 (4) 0 (0)
Disease (%)
 AML / AML from MDS 14 (50) 9 (45)
 ALL 2 (7) 2 (10)
 CML 1 (4) 0 (0)
 CLL 2 (7) 4 (20) .81
 MDS 4 (14) 2 (10)
 NHL 1 (4) 2 (10)
 MM 1 (4) 0 (0)
 AA 2 (7) 0 (0)
 HL 1 (4) 1 (5)

AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma.

*

Included 22 patients who had never developed cGVHD and 6 patients with resolved or inactive cGVHD on date of sample collection.

On date of sample collection.